Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
RETROSPECTIVE SURVEY OF FLUOROQUINOLONE U SE IN CHILDREN
Autore:
PARIENTEKHAYAT A; VAUZELLEKERVROEDAN F; DATHIS P; BREART G; GENDREL D; AUJARD Y; OLIVE G; PONS G;
Indirizzi:
UNIV PARIS 05,DEPT PHARMACOL PERINATALE & PEDIAT,82 AVE DENFERT ROCHEREAU F-75674 PARIS 14 FRANCE UNIV PARIS 05,DEPT PHARMACOL PERINATALE & PEDIAT F-75674 PARIS 14 FRANCE UNIV PARIS 05,DEPT PEDIAT,HOP ST VINCENT DE PAUL F-75674 PARIS 14 FRANCE HOP COCHIN,UNITE RECH EPIDEMIOL SANTE FEMMES & ENFANTS,INSERM,U149 F-75674 PARIS 14 FRANCE HOP ROBERT DEBRE,DEPT PEDIAT F-75019 PARIS FRANCE
Titolo Testata:
Archives de pediatrie
fascicolo: 5, volume: 5, anno: 1998,
pagine: 484 - 488
SICI:
0929-693X(1998)5:5<484:RSOFUS>2.0.ZU;2-6
Fonte:
ISI
Lingua:
FRE
Soggetto:
CYSTIC-FIBROSIS; ANAPHYLACTOID REACTIONS; PEDIATRIC-PATIENTS; CIPROFLOXACIN; PEFLOXACIN; ARTHROPATHY; POLYARTHROPATHY; QUINOLONES; ADOLESCENT; TOLERANCE;
Keywords:
QUINOLONES; RETROSPECTIVE STUDIES; CHILD; PHARMACOLOGY, CLINICAL; EPIDEMIOLOGY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
29
Recensione:
Indirizzi per estratti:
Citazione:
A. Parientekhayat et al., "RETROSPECTIVE SURVEY OF FLUOROQUINOLONE U SE IN CHILDREN", Archives de pediatrie, 5(5), 1998, pp. 484-488

Abstract

Background. - Fluoroquinolones (FQ) are contraindicated in children because of the risk of cartilage damage. Population and methods. - A retrospective survey concerning the use of Fe in children during the first 6 months of 1993 was organized in 1994. One hundred and sixty-sevenHeads of pediatric departments were questioned Results. - One hundredand fifty (90%) of those surveyed responded: 62 (41.3%) were FQ prescribers. 83 (55.3%) were non prescribers and five (3.4%) were not able to answer. Among the 62 prescribers of FQ, 17 departments (27%) were nor able to indicate the number of prescriptions and 45 departments (73%) reported one to 75 prescriptions during the study period. Twenty-one departments out of the 45 were not able to identify the children treated with FQ. We obtained a group of 104 children aged 9.0 +/- 5.0 years (mean +/- standard deviation [SD]), treated with 165 courses of FQ during 20 +/- 45 days (1-535 days) with concomitant treatments for 132/165 courses (80%). Fifty children (48%) were suffering from cystic fibrosis, 37 children (36%) were not, and, in 17 the diagnosis was not determined (16%). The Fe treatment administered either orally (73%) or intravenously (26%) was ciprofloxacin in 69% of the courses with a 25.1 +/- 7.0 mg/kg/day oral dose (mean +/- SD dose), and a 23.5 +/- 11.4 mg/kg/day intravenous dose, pefloxacin in 23 courses/165 (14%) with a 17.2 +/- 3.8 mg/kg/day dose, ofloxacin in 15 courses/165 (9%) with a 21.0 +/- 11.9 mg/kg/day dose, norfloxacin in 13 courses/165 (8%) with a25.6 +/- 7.5 mg/kg/day dose. Twenty-one adverse events were reported in 17 children (16%) (11 of them with cystic fibrosis). These were cutaneous events (photosensitivity, cutaneous eruption) in eight courses,rheumatologic events (arthralgia, arthritis) in seven courses and gastrointestinal events (nausea, vomiting, diarrhea) in three courses. Conclusion. - This survey shows that Fe are prescribed in children although their use is not approved in this age group and that numerous sideeffects have been recorded. The absence of exhaustive information (due to the retrospective nature of the survey) and the difficulties in interpreting the side effects for which validity and causal assessment have not been worked our according to a standardized method and in theabsence of a control group stress the need for a prospective study. (C) 1998, Elsevier, Paris.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 15/01/21 alle ore 23:14:50